Circassia is a world-class specialty biopharmaceutical business focused on allergy and asthma. It’s most advanced product is currently in Phase III testing for cat allergy, and is the first in a new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). Three other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies. Circassia's lead asthma product targets substitution of GSK's Flixotide® pMDI, and received market approval for the UK in November 2015.
The Company has an established commercial infrastructure, marketed products, a pipeline of near-term therapies and a portfolio of next generation treatments targeting multi-$billion market opportunities. Circassia sells its novel, market-leading products for asthma management directly to allergy / asthma specialists in the United States and Germany. Its products are also promoted in a number of other countries by the Company's international network of partners.
Steve co-founded Circassia in 2006 and has led the company as Chief Executive Officer since then.
He is a bioscience entrepreneur with extensive experience in the founding and leading of specialty pharma companies including Zeneus Pharma and Powderject Pharmaceutical.
Receives first marketing approval for its fluticasone propionate pressurised metered dose inhaler using only in vitro results.Read more
Circassia completes placing and raises £275 million to fund acquisitions of Aerocrine and ProsonixRead more
Recruitment for pivotal phase III trial for cat allergy treatment completeRead more
Positive top-line results for a phase IIb clinical study of HDM-SPIRE, a house dust mite allergy product candidate based on Circassia’s proprietary ToleroMune® platform technology.Read more
Circassia admitted to trade on the London Stock ExchangeRead more
Grass allergy treatment achieves significant system reduction during Hay Fever seasonRead more
Short course house dust mite allergy treatment achieves significant long-term symptom reductionRead more
Toleromune cat allergy treatment shown to maintain symptom improvement two years after the start of short course therapyRead more
Circassia receives outstanding abstract awards at 2012 World Allergy Organization International Scientific ConferenceRead more
Start of pivotal phase III Toleromune trial in Cat Allergen-Induced RhinoconjunctivitisRead more
Joint venture with McMaster University initiates clinical studies to explore biomarkers of Toleromune treatment effectiveness
NIH Awards $6.4 Million to Professor Mark Larché to Investigate Mechanisms of Allergy Tolerance Generated by Circassia’s ToleroMune® Treatment
Draws down £35m funding from investors following milestone completion and raises further £12m
Ragweed allergy therapy achieves positive phase II clinical results
Circassia Successfully Completes Observational Study to Inform Design of Cat Allergy Treatment Phase III Trial
Announces grant of european patents for key peptides in grass and ragweed allergy therapies
Positive phase II trial results for Toleromune hayfever vaccine, which substantially improved patients’ allergy symptoms
Circassia announces £60m fundraisingRead more